References
- Matera MG, Rogliani P, Calzetta L, et al. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opin Drug Metab Toxicol. 2018;14:239-245.
- Nixon J, Newbold P, Mustelin T, et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther. 2017;169:57–77.
- Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am. 2007;27:623–632.
- Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033–1039.
- Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
- Global Initiative for Asthma. Global strategy for asthma management and prevention. [cited 2017 Dec 28]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/
- Walker JA, Barlow JL, McKenzie ANJ. Innate lymphoid cells - how did we miss them? Nat Rev Immunol. 2013;13:75–87.
- Broughton SE, Dhagat U, Hercus TR, et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2012;250:277–302.
- Bischoff SC, Brunner T, De Weck AL, et al. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med. 1990;172:1577–1582.
- Huang CD, Wang CH, Liu CY, et al. Eosinophils from asthmatics release IL-5 in an autocrine fashion to prevent apoptosis through upregulation of Bcl-2 expression. J Asthma. 2005;42:395–403.
- Shi HZ, Xiao CQ, Zhong D, et al. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med. 1998;157:204–209.
- Robinson D, Hamid Q, Bentley A, et al. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol. 1993;92:313–324.
- Wauwe JV. Interleukin-5 as a potential target for asthma treatment. Drug News Perspect. 2000;13:197–205.
- Chung KF. Clinical management of severe therapy-resistant asthma. Expert Rev Respir Med. 2017;11:395–402.
- Kita H. Eosinophils: multifaceted biological properties and roles in health and disease. Immunol Rev. 2011;242:161–177.
- Gleich GJ, Klion AD, Lee JJ, et al. The consequences of not having eosinophils. Allergy. 2013;68:829–835.
- Kung TT, Stelts DM, Zurcher JA, et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol. 1995;13:360–365.
- Mauser PJ, Pitman AM, Fernandez X, et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med. 1995;152:467–472.
- Herndon FJ, Kayes SG. Depletion of eosinophils by anti-IL-5 monoclonal antibody treatment of mice infected with Trichinella spiralis does not alter parasite burden or immunologic resistance to reinfection. J Immunol. 1992;149:3642–3647.
- Sher A, Coffman RL, Hieny S, et al. Interleukin 5 is required for the blood and tissue eosinophilia but not granuloma formation induced by infection with Schistosoma mansoni. Proc Natl Acad Sci. 1990;87:61–65.
- Gatault S, Legrand F, Delbeke M, et al. Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother. 2012;61:1527–1534.
- Carretero R, Sektioglu IM, Garbi N, et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(?) T cells. Nat Immunol. 2015;16:609–617.
- Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2017;7(2):e1393134.
- Jensen-Jarolim E, Bax HJ, Bianchini R, et al. The impact of allergy in oncology: EAACI position paper. Allergy. 2017;72(6):866–887.
- Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010;185:7443–7451.
- Long H, Liao W, Wang L, et al. A player and coordinator: the versatile roles of eosinophils in the immune system. Transfus Med Hemother. 2016;43:96–108.
- Wen T, Rothenberg ME. The regulatory function of eosinophils. Microbiol Spectr. 2016;4. DOI:10.1128/microbiolspec.MCHD-0020-2015
- Iwamoto N, Hamada A, Shimada T. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis. Anal Biochem. 2018;540-541:30–37.
- Bousquet J, Chiron R, Humbert M. Biologics in asthma: difficulties and drawbacks. Expert Opin Biol Ther. 2008;8:1921–1928.
- Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65:657–661.
- Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61:912–920.
- Matucci A, Nencini F, Pratesi S, et al. An overview on safety of monoclonal antibodies. Curr Opin Allergy Clin Immunol. 2016;16:576–581.
- CINQAIR product monograph. [cited 2018 Feb 24]. Available from: http://www.tevacanadainnovation.com/downloads/Cinqair_PM_EN.pdf; http://www.tevacanadainnovation.com/downloads/Cinqair_PM_EN.pdf; http://www.tevacanadainnovation.com/downloads/Cinqair_PM_EN.pdf
- CINQAERO, INN-reslizumab - Europa EU. Summary of product characteristics. [cited 2017 Dec 29]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003912/WC500212250.pdf
- CINQAERO, Assessment report. [cited 2018 Feb 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003912/WC500212252.pdf
- Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma. Am J Respir Crit Care Med. 2003;167:1655–1659.
- Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184:1125–1132.
- Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366.
- Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–798.
- Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150:799–810.
- Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: a systematic review and meta-analysis. J Asthma. 2017;54:300–307.
- Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5:1572–81.e3).
- Hom S, Pisano M. Reslizumab (Cinqair). An interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. P&T. 2017;42:564–568.
- National Institute for Health and Care Excellence. Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids [ID872]. [cited 2017 Dec 29]. Available from: https://www.nice.org.uk/guidance/ta479/documents/committee-papers
- Sullivan PW, Ghushchyan VH, Globe G, et al. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110–116.e7.
- Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc). 2012;48:785–794.
- Bernstein DI, Mansfield L, Zangrilli J, et al. Efficacy of reslizumab in older patients (>65 years) with asthma and elevated blood eosinophils: results from a pooled analysis of two phase 3, placebo-controlled trials [abstract]. J Allergy Clin Immunol. 2016;137:AB86.
- Center for Drug Evaluation and Research. Application number: 761033Orig1s000. Other Review(s). [cited 2017 Dec 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/nda/2016/761033Orig1s000OtherR.pdf
- Takeda K, Shiraishi Y, Ashino S, et al. Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge. J Allergy Clin Immunol. 2015;135:451–460.
- Cheung DS, Grayson MH. A survivor: the eosinophil as a regulator in asthma. J Allergy Clin Immunol. 2015;135:461–462.
- Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121:1473–83.83e1-4.
- Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103:2939–2941.
- Ikutani M, Yanagibashi T, Ogasawara M, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188:703–713.
- Jin JJ, Butterfield JH, Weiler CR. Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes. J Allergy Clin Immunol Pract. 2015;3:920–925.